Company Overview
Cardiol Therapeutics is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart diseases
The Company brings together a wealth of research and development experience, advanced manufacturing capabilities, and a Management team, Board of Directors, and Scientific Advisory Board comprising business and thought leaders with extensive industry experience and expertise in commercializing prescription medicines. Learn more…
Cardiol’s lead product candidate, CardiolRx™, is a pharmaceutically manufactured oral cannabidiol formulation that is being clinically developed for use in heart diseases. Learn more…
CardiolRx™ is currently being evaluated in a Phase II multi-national, double-blind, randomized, placebo-controlled clinical study (the “ARCHER” trial). ARCHER is designed to study the safety and tolerability of CardiolRx™, as well as its impact on myocardial recovery, in patients presenting with acute myocarditis. This disease is an important cause of acute and fulminant heart failure in young adults and a leading cause of sudden cardiac death in people less than 35 years of age. The Company believes there is a significant opportunity to develop an important new therapy for acute myocarditis, for which there is currently no accepted standard of care, that would also be eligible for designation as an orphan drug in the United States. Learn more…
The Company has also received Investigational New Drug Application (“IND”) authorization from the United States Food and Drug Administration (“FDA”) conduct a Phase II open-label pilot study designed to evaluate the tolerance and safety of CardiolRx™ in patients with recurrent pericarditis (inflammation of the pericardium). The study will also assess the improvement in objective measures of disease, and during an extension period, assess the feasibility of weaning concomitant background therapy including corticosteroids while taking CardiolRx™. Recurrent pericarditis is the most common of pericardial diseases with symptoms that include debilitating chest pain, shortness of breath, and fatigue. Further, up to 50% of patients with a recurrent episode of pericarditis experience more recurrences. Recurrent pericarditis is an orphan disease in the United States, thereby making CardiolRx™ eligible for orphan drug status under the FDA’s Orphan Drug Designation program. Learn more…
In addition, the Company is developing a subcutaneous formulation of cannabidiol targeting the inflammation and fibrosis associated with the development and progression of heart failure – a leading cause of death and hospitalization in the developed world, with associated healthcare costs in the U.S. exceeding $30 billion annually. Learn more…
